WO2006034343A3 - methods for regulating neurotransmitter systems by inducing counteradaptations - Google Patents

methods for regulating neurotransmitter systems by inducing counteradaptations Download PDF

Info

Publication number
WO2006034343A3
WO2006034343A3 PCT/US2005/033826 US2005033826W WO2006034343A3 WO 2006034343 A3 WO2006034343 A3 WO 2006034343A3 US 2005033826 W US2005033826 W US 2005033826W WO 2006034343 A3 WO2006034343 A3 WO 2006034343A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
regulating
neurotransmitter systems
inducing
neurotransmitter
Prior art date
Application number
PCT/US2005/033826
Other languages
French (fr)
Other versions
WO2006034343A2 (en
Inventor
Alexander Michalow
Original Assignee
Alexander Michalow
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexander Michalow filed Critical Alexander Michalow
Priority to JP2007533610A priority Critical patent/JP2008514612A/en
Priority to EP05800810A priority patent/EP1809104A4/en
Priority to CA002580694A priority patent/CA2580694A1/en
Priority to AU2005286733A priority patent/AU2005286733B2/en
Publication of WO2006034343A2 publication Critical patent/WO2006034343A2/en
Publication of WO2006034343A3 publication Critical patent/WO2006034343A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention relates to methods for regulating neurotransmitter systems by inducing a counteradaptation response. According to one embodiment of the invention, a method for regulating a neurotransmitter includes the step of repeatedly administering a ligand for a receptor in the neurotransmitter system, with a ratio of administration half-life to period between administrations of no greater than 1/2. The methods of the present invention may be used to address a whole host of undesirable mental and neurological conditions.
PCT/US2005/033826 2004-09-23 2005-09-23 methods for regulating neurotransmitter systems by inducing counteradaptationS WO2006034343A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2007533610A JP2008514612A (en) 2004-09-23 2005-09-23 Methods of modulating neurotransmitter systems by inducing counter adaptation
EP05800810A EP1809104A4 (en) 2004-09-23 2005-09-23 Methods for regulating neurotransmitter systems by inducing counteradaptations
CA002580694A CA2580694A1 (en) 2004-09-23 2005-09-23 Methods for regulating neurotransmitter systems by inducing counteradaptations
AU2005286733A AU2005286733B2 (en) 2004-09-23 2005-09-23 Methods for regulating neurotransmitter systems by inducing counteradaptations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61215504P 2004-09-23 2004-09-23
US60/612,155 2004-09-23

Publications (2)

Publication Number Publication Date
WO2006034343A2 WO2006034343A2 (en) 2006-03-30
WO2006034343A3 true WO2006034343A3 (en) 2006-10-05

Family

ID=36090649

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/033826 WO2006034343A2 (en) 2004-09-23 2005-09-23 methods for regulating neurotransmitter systems by inducing counteradaptationS

Country Status (7)

Country Link
US (3) US20060069086A1 (en)
EP (1) EP1809104A4 (en)
JP (2) JP2008514612A (en)
CN (1) CN101065014A (en)
AU (1) AU2005286733B2 (en)
CA (1) CA2580694A1 (en)
WO (1) WO2006034343A2 (en)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1121111T3 (en) 1998-10-15 2010-05-31 Imp Innovations Ltd Compounds for the treatment of weight loss
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
US20040204862A1 (en) * 2003-04-11 2004-10-14 Wainer Irving W. Computer-based model for identification and characterization for non-competitive inhibitors of nicotinic acetylcholine receptors and related ligand-gated ion channel receptors
RU2350327C2 (en) 2003-04-29 2009-03-27 Ориксиджен Серапьютикс, Инкорпорэйтд Compounds causing weight loss
DE602006014480D1 (en) * 2005-09-08 2010-07-08 Texcontor Ets Lofexidine for intraspinal use
EP3132792B1 (en) 2005-11-22 2019-09-11 Nalpropion Pharmaceuticals, Inc. Composition and methods for increasing insulin sensitivity
DK1954669T3 (en) 2005-12-01 2015-10-12 Auspex Pharmaceuticals Inc SUBSTITUTED phenethylamines a serotonergic AND / OR NOREPINEPHRINERG ACTIVITY
AU2006326377B2 (en) * 2005-12-13 2010-10-07 Biodelivery Sciences International, Inc. Abuse resistant transmucosal drug delivery device
JP2009528289A (en) * 2006-02-27 2009-08-06 ミシャロウ、アレクサンダー Methods of modulating neurotransmitter systems by inducing counter adaptation
US20070259939A1 (en) * 2006-05-04 2007-11-08 Accelerated Technologies Using naltrexone as a multi-purpose health supplement to improve the human condition and preventing multiple diseases and infirmities by stimulating immune system vitality and robustness
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
KR101230804B1 (en) 2006-07-21 2013-02-08 바이오딜리버리 사이언시스 인터내셔널 인코포레이티드 Transmucosal delivery devices with enhanced uptake
US7820689B2 (en) * 2006-08-10 2010-10-26 Hua-Lin Wu Methods and compositions for preventing or treating cardiovascular disease
KR101479324B1 (en) 2006-11-09 2015-01-05 오렉시젠 세러퓨틱스 인크. Layered pharmaceutical formulations comprising an intermediate rapidly dissolving layer
KR20140088619A (en) 2006-11-09 2014-07-10 오렉시젠 세러퓨틱스 인크. Unit dosage packages
GB0624282D0 (en) 2006-12-05 2007-01-10 Cavalla David Treatment of cachexia
FR2912058A1 (en) * 2007-02-07 2008-08-08 Sanofi Aventis Sa Treatment or prevention of sexual dysfunction, e.g. lack of sexual desire or erectile dysfunction, uses neurokinin A NK2 receptor antagonist, e.g. sareductant
EP3103790B1 (en) 2007-03-15 2018-05-09 Auspex Pharmaceuticals, Inc. Substituted phenethylamine with serotoninergic and/or norepinephrinergic activity
AT505086B1 (en) * 2007-04-02 2009-06-15 Planta Naturstoffe Vertriebsge PHARMACEUTICAL AGENT AGAINST JUCKREIZ AND JUCKREIZED PAIN
JP2010526825A (en) * 2007-05-10 2010-08-05 エーエムアール テクノロジー インコーポレイテッド Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and their use to block reuptake of norepinephrine, dopamine and serotonin
JP5566282B2 (en) * 2007-05-10 2014-08-06 アルバニー モレキュラー リサーチ， インコーポレイテッド Aryloxy- and heteroaryloxy-substituted tetrahydrobenzazepines and their use to block norepinephrine, dopamine and serotonin reuptake
EP2168580B1 (en) * 2007-06-22 2015-12-02 Toray Industries, Inc. Remedy or preventive for schizophrenia
JP2011500686A (en) * 2007-10-18 2011-01-06 アイコ バイオテクノロジー Combined analgesics using opioids and neutral antagonists
US8748448B2 (en) 2007-10-18 2014-06-10 Aiko Biotechnology Combination analgesic employing opioid agonist and neutral antagonist
WO2010036401A1 (en) * 2008-05-01 2010-04-01 The Regents Of The University Of California Methods and compositions using selective delta opioid receptor-1 agonists, delta opioid receptor-2 antagonists, and/or mu opioid receptor antagonists for treatment of substance-related disorders
MX2010012909A (en) * 2008-05-30 2011-02-25 Orexigen Therapeutics Inc Methods for treating visceral fat conditions.
PT2379066E (en) * 2008-09-16 2014-07-04 Imuneks Farma Ilaç Sanayi Ve Ticaret A S Use of opioid antagonists for the preparation of a medicament in the treatment of retinal degenerative diseases
TWI546537B (en) * 2009-05-19 2016-08-21 維維亞生技公司 Methods for providing personalized medicine tests ex vivo for hematological neoplasms
WO2011087755A2 (en) * 2009-12-22 2011-07-21 Pondera Biotechnologies, LLC Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications
JP6196041B2 (en) 2010-01-11 2017-09-13 オレキシジェン・セラピューティクス・インコーポレーテッド Methods for providing weight loss therapy in patients with major depression
TR201002473A2 (en) 2010-03-31 2011-09-21 Mustafa Nevzat �La� Sanay�� A.�. A method of treating herpes zoster disease using an opiate receptor antagonist.
CA3119258A1 (en) 2011-08-18 2013-02-21 Biodelivery Sciences International, Inc. Abuse-resistant mucoadhesive devices for delivery of buprenorphine
US9901539B2 (en) 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief
MA37714A1 (en) 2012-06-06 2017-12-29 Orexigen Therapeutics Inc Methods of treating overweight and obesity
US8974365B2 (en) 2012-11-25 2015-03-10 Steven Richard Devore Best Treatment of thalamocortical dysrhythmia
CN104955483A (en) * 2013-01-30 2015-09-30 法莫斯医疗公司 Treatments for depression and other diseases with a low dose agent
JP6188933B2 (en) 2013-10-07 2017-08-30 テイコク ファーマ ユーエスエー インコーポレーテッド Methods and compositions for transdermal delivery of non-sedating amounts of dexmedetomidine
CA2924231C (en) 2013-10-07 2018-04-03 Teikoku Pharma Usa, Inc. Dexmedetomidine transdermal delivery devices and methods for using the same
CN106456561B (en) 2013-10-07 2020-02-28 帝国制药美国公司 Methods and compositions for treating attention deficit hyperactivity disorder, anxiety disorders, and insomnia using dexmedetomidine transdermal compositions
MA41689A (en) * 2014-10-15 2017-08-22 Bioxcel Corp PREVENTION OR TREATMENT OF SLEEP DISORDERS WITH A DEXMEDETOMIDINE FORMULATION
CN106008672B (en) * 2016-06-20 2020-06-16 郑州大学 Synthetic peptide NK3R-A2 based on NK3 receptor and application thereof
CN106008673B (en) * 2016-06-20 2020-06-16 郑州大学 Synthetic peptide NK3R-A1 based on NK3 receptor and application thereof
KR20240031326A (en) 2016-12-31 2024-03-07 바이오엑셀 테라퓨틱스 인코포레이티드 Use of Sublingual Dexmedetomidine for the treatment of Agitation
WO2019171333A1 (en) * 2018-03-08 2019-09-12 Victoria Link Ltd Treatment of demyelinating diseases
CA3103431A1 (en) 2018-06-27 2020-01-02 Bioxcel Therapeutics, Inc. Film formulations containing dexmedetomidine and methods of producing them
EP3938375A4 (en) * 2019-03-14 2022-12-21 Lactocore, Inc. Synthetic neuromodulatory peptides
CA3145388A1 (en) 2019-07-19 2021-01-28 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025157A (en) * 1997-02-18 2000-02-15 Genentech, Inc. Neurturin receptor
US6166008A (en) * 1997-10-27 2000-12-26 Cortex Pharmaceuticals, Inc. Treatment of schizophrenia with ampakines and neuroleptics

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3980641A (en) * 1975-07-31 1976-09-14 Bristol-Myers Company Process for the preparation of 14-hydroxymorphinans
US4081434A (en) * 1977-03-11 1978-03-28 Hoffmann-La Roche Inc. Novel analogs of β-endorphin
US4217353A (en) * 1978-05-19 1980-08-12 E. I. Du Pont De Nemours And Company Method for inducing anorexia
US4272540A (en) * 1979-04-24 1981-06-09 Sisa, Incorporated 14-Methoxymorphinan-6-one compounds and therapeutic methods of treating pain and drug dependence with them
US4377595A (en) * 1979-08-13 1983-03-22 Massachusetts Institute Of Technology Process for reducing depression
US4322426A (en) * 1980-04-28 1982-03-30 E. I. Du Pont De Nemours And Company 17-Substituted-6-desoxy-7,8-dihydro-6α-methylnoroxymorphone narcotic antagonists
EP0077122B1 (en) * 1981-09-15 1986-05-07 Imperial Chemical Industries Plc Amino-substituted tetralins and related homocyclic compounds
ATE18201T1 (en) * 1981-09-25 1986-03-15 Wellcome Found AMIDES WITH PHARMACOLOGICAL ACTIVITY, PREPARATION AND AGENTS CONTAINING THESE COMPOUNDS AND USE.
US4801614A (en) * 1981-10-05 1989-01-31 Tni Pharmaceuticals, Inc. Process for using endogenous enkephalins and endorphins to inhibit growth of tumerous cells
US4537878A (en) * 1981-10-05 1985-08-27 Tni Pharmaceuticals, Inc. Process for using endogenous enkephalins and endorphins to stimulate the immune system
US4757049A (en) * 1981-10-05 1988-07-12 Tni Pharmaceuticals, Inc. Process for using endogenous enkephalins and endorphins to stimulate the immune system of patients with aids
US4462941A (en) * 1982-06-10 1984-07-31 The Regents Of The University Of California Dynorphin amide analogs
US4468383A (en) * 1982-09-29 1984-08-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Service Dimeric enkephalins
US4567185A (en) * 1983-05-13 1986-01-28 Key Pharmaceuticals, Inc. Endorphin blockage
US4518711A (en) * 1983-05-16 1985-05-21 Gibson-Stephens Institute Conformationally constrained cyclic enkephalin analogs with delta receptor specificity
US4535157A (en) * 1983-11-01 1985-08-13 Key Pharmaceuticals, Inc. Process for making 6-desoxy-6-methylenenaloxone and 6-desoxy-6-methylenenaltrexone
US4684624A (en) * 1983-12-22 1987-08-04 Yoshio Hosobuchi Method of treating cerebral ischemia
IT1206339B (en) * 1984-01-13 1989-04-14 Anic Spa HEXAPEPTID RETRO INVERTED ANALOGS C-TERMINALS OF THE SUBSTANCE P.
US5266574A (en) * 1984-04-09 1993-11-30 Ian S. Zagon Growth regulation and related applications of opioid antagonists
US4689332A (en) * 1984-04-09 1987-08-25 Research Corporation Growth regulation and related applications of opioid antagonists
US4668685A (en) * 1984-07-05 1987-05-26 E.I. Du Pont De Nemours And Company Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists
US4684620A (en) * 1984-09-04 1987-08-04 Gibson-Stephens Neuropharmaceuticals, Inc. Cyclic polypeptides having mu-receptor specificity
US4600718A (en) * 1984-09-18 1986-07-15 Huebner Hans F Method of treating weight loss disorders
US4680283A (en) * 1984-09-26 1987-07-14 Merck & Co., Inc. Analogs of substance P and eledoisin
US4573995A (en) * 1984-10-09 1986-03-04 Alza Corporation Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine
US4910152A (en) * 1985-01-31 1990-03-20 Meyers Vera K Method for binding opioid receptors
US4761429A (en) * 1985-07-22 1988-08-02 Kenneth Blum Enkephalinase and endorphinase inhibitors as anti-craving compositions
US4990617A (en) * 1985-12-02 1991-02-05 E. I. Du Pont De Nemours And Company N-oxide prodrug derivatives of 3-hydroxy morphinans and partial morphinans and derivatives
US4758562A (en) * 1985-12-18 1988-07-19 Temple University Of The Commonwealth System Of Higher Education Method for inducing hypothermia and/or poikilothermia
US4910153A (en) * 1986-02-18 1990-03-20 Solarex Corporation Deposition feedstock and dopant materials useful in the fabrication of hydrogenated amorphous silicon alloys for photovoltaic devices and other semiconductor devices
US4673679A (en) * 1986-05-14 1987-06-16 E. I. Du Pont De Nemours And Company Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration
US4767764A (en) * 1986-05-27 1988-08-30 E. I. Du Pont De Nemours And Company Alkoxyalkyl and alkylmercaptoalkyl substituted bridged benzofuroisoquinolines having opioid antagonist and/or appetite-controlling properties
US5013739A (en) * 1986-10-07 1991-05-07 Bernard Bihari Method of treating chronic fatigue syndrome using an opiate receptor antagonist
US6586443B1 (en) * 1986-10-07 2003-07-01 Bernard Bihari Method of treating multiple sclerosis
US5246941A (en) * 1986-12-17 1993-09-21 Glaxo Group Limited Method for the treatment of depression
US4839465A (en) * 1987-01-20 1989-06-13 Sterling Drug Inc. Di-(D-tryptophyl and/or tetrahydropyridoindolylcarbonyl)-containing peptide amides and process for preparation thereof
US5025018A (en) * 1987-06-05 1991-06-18 Medicis Corporation Central nervous system injury treatment with opiate-receptor antagonist
CA1335227C (en) * 1987-06-22 1995-04-11 Wylie W. Vale, Jr. Crf analog conjugates
US4816586A (en) * 1987-07-29 1989-03-28 Regents Of The University Of Minnesota Delta opioid receptor antagonists
US5410019A (en) * 1987-09-24 1995-04-25 The Administrators Of The Tulane-Educational Fund Therapeutic peptides
US5137673A (en) * 1987-11-17 1992-08-11 Monsanto Company Process for forming plasticized polyvinyl butyral sheet
US4912114A (en) * 1988-03-18 1990-03-27 Sandoz Ltd. Morphinan derivatives
KR910001937Y1 (en) * 1988-05-18 1991-03-30 삼성전자 주식회사 Analog switch circuit
US5278146A (en) * 1988-09-30 1994-01-11 The Salk Institute For Biological Studies CRF analogs
US4857533A (en) * 1988-12-15 1989-08-15 Baker Cummins Pharmaceuticals, Inc. Method of treatment for autoimmune diseases
FR2646347B1 (en) * 1989-04-28 1991-08-23 Roussel Uclaf NOVEL HYDROXYPHENETHYLAMINE DERIVATIVE AND ITS SALTS, METHOD OF PREPARATION, APPLICATION AS MEDICAMENTS AND USE AS A SPECIFIC PHARMACOLOGICAL TOOL
US5017689A (en) * 1989-07-06 1991-05-21 Arizona Technology Development Corporation Dynorphin analogs specific for kappa opioid receptors
US5096715A (en) * 1989-11-20 1992-03-17 Alko Ltd. Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist
JP2906654B2 (en) * 1989-11-28 1999-06-21 東レ株式会社 Immunosuppressant and method for producing the same
US5028612A (en) * 1990-03-22 1991-07-02 Hillel Glover Method for treating emotional numbness
US5013740A (en) * 1990-03-22 1991-05-07 Hillel Glover Method for treating emotional numbness and coma
US5616562A (en) * 1990-04-27 1997-04-01 Murphy; Christopher J. Methods and compositions using substance P to promote wound healing
US5137873A (en) * 1990-07-27 1992-08-11 The Children's Medical Center Corporation Substance p and tachykinin agonists for treatment of alzheimer's disease
GB9202238D0 (en) * 1992-02-03 1992-03-18 Wellcome Found Compounds
US6271239B1 (en) * 1992-04-13 2001-08-07 Regents Of The University Of Minnesota Delta opioid receptor-selective benzylidene-substituted morphinans
US5326751A (en) * 1992-06-26 1994-07-05 Arizona Board Of Regents On Behalf Of The University Of Arizona Enkephalin analogs
SE9203496D0 (en) * 1992-11-20 1992-11-20 Kabi Pharmacia Ab NEW OLIGOPEPTIDES
US5817628A (en) * 1992-12-02 1998-10-06 The Rockefeller University Dynorphin a suppression of natural killer cell activity
US6369074B1 (en) * 1992-12-10 2002-04-09 Pfizer Inc. Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists
SE9300012D0 (en) * 1993-01-05 1993-01-05 Astra Ab NEW PEPTIDES
FR2700472B1 (en) * 1993-01-19 1995-02-17 Rhone Poulenc Rorer Sa Synergizing association having an antagonistic effect on the NK1 and NK2 receptors.
US5512593A (en) * 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
US5891842A (en) * 1993-04-09 1999-04-06 Trustees Of Tufts College Methodology for eliciting an analgesic response in a living subject
US6096513A (en) * 1993-05-20 2000-08-01 Arch Development Corporation Polynucleotides encoding KAPPA opiod receptors
US5457208A (en) * 1993-06-21 1995-10-10 Regents Of The University Of Minnesota Kappa opioid receptor antagonists
US5395398A (en) * 1993-07-28 1995-03-07 C. R. Bard, Inc. Microelectric apparatus for the antisepsis, promulgation of healing and analgesia of wound and chronic skin ulcers
US5411965A (en) * 1993-08-23 1995-05-02 Arizona Board Of Regents Use of delta opioid receptor antagonists to treat cocaine abuse
US5464841A (en) * 1993-11-08 1995-11-07 Univ Minnesota Use of delta opioid receptor antagonists to treat immunoregulatory disorders
SE9503924D0 (en) * 1995-08-18 1995-11-07 Astra Ab Novel opioid peptides
IT1269826B (en) * 1994-05-24 1997-04-15 Paolo Minoia USE OF OPTIACEAN ANTAGONISTS AND CALCIUM SALTS FOR THE PREPARATION OF MEDICATIONS FOR THE TREATMENT OF ENDORPHINE-MEDIATED PATHOLOGICAL FORMS
DE69535486T2 (en) * 1994-06-15 2008-04-10 Otsuka Pharmaceutical Co., Ltd. Benzoheterocyclic compounds useful as vasopressin or oxytocin modulators
JP3155008B2 (en) * 1994-07-26 2001-04-09 ファイザー・インコーポレーテッド 4-indole derivatives as serotonin agonists and antagonists
JPH10513471A (en) * 1995-02-10 1998-12-22 メドトロニック、インコーポレイテッド Methods and devices for the administration of analgesics
FR2732221B1 (en) * 1995-03-28 1997-04-25 Oreal USE OF A CGRP ANTAGONIST TO TREAT CUTANEOUS REDNESS OF NEUROGENIC ORIGIN AND COMPOSITION OBTAINED
IT1275433B (en) * 1995-05-19 1997-08-07 Smithkline Beecham Farma DIARYLDIAMINE DERIVATIVES
US5610271A (en) * 1995-06-07 1997-03-11 Torrey Pines Institute For Molecular Studies Kappa receptor selective opioid peptides
US6214797B1 (en) * 1995-06-13 2001-04-10 The Salk Institute For Biological Studies Urocortin peptides, nucleic acid encoding same methods for using same
IT1277597B1 (en) * 1995-09-15 1997-11-11 Smithkline Beecham Spa DIARYLALKENYLAMINE DERIVATIVES
CA2220768A1 (en) * 1996-03-13 1997-09-18 Yale University Smoking cessation treatments using naltrexone and related compounds
US6737397B1 (en) * 1996-03-29 2004-05-18 The Penn State Research Foundation Control of cancer growth through the interaction of [MET5]-enkephalin and the zeta receptor
WO1997045119A1 (en) * 1996-05-24 1997-12-04 Novartis Ag Use of substance p antagonists for treating social phobia
US5945508A (en) * 1996-07-23 1999-08-31 Witten; Mark L. Substance P treatment for immunostimulation
AU3708397A (en) * 1996-08-02 1998-02-25 Kaneka Corporation Sulfonic ester derivatives, process for preparing the same, and use thereof
US6440987B1 (en) * 1996-11-25 2002-08-27 Toray Industries, Inc. Antipruritic
CN1291717C (en) * 1996-11-25 2006-12-27 东丽株式会社 Antipruritic
EP0946157B1 (en) * 1996-12-16 2002-03-13 Alcon Laboratories, Inc. The topical use of kappa opioid agonists to treat ocular pain
GB9709972D0 (en) * 1997-05-19 1997-07-09 Pfizer Ltd Tetrazoles
US6063758A (en) * 1997-07-09 2000-05-16 Advanced Targeting Systems, Inc. Substance P-Saporin (SP-SAP) conjugates and methods of use thereof
US6194407B1 (en) * 1997-07-30 2001-02-27 American Home Products Corporation Tricyclic pyrido vasopressin agonists
US5922361A (en) * 1997-08-11 1999-07-13 Bieser; Albert Howard Folic acid enriched dietary supplement compositions for self-regulating stress-reduction
JP4359711B2 (en) * 1997-09-02 2009-11-04 東レ株式会社 Drug addiction treatment
US6437092B1 (en) * 1998-11-06 2002-08-20 Conjuchem, Inc. Conjugates of opioids and endogenous carriers
EP0957099B1 (en) * 1998-04-15 2002-11-20 Pfizer Products Inc. Heterocyclic carboxamides
GB9815618D0 (en) * 1998-07-18 1998-09-16 Univ Manchester Treatment of dyskinesia
US6090803A (en) * 1998-07-24 2000-07-18 American Home Products Corporation Tricyclic vasopressin agonists
ES2150378B1 (en) * 1998-08-07 2001-07-01 Esteve Labor Dr EMPLOYMENT OF ARIL (OR HETEROARIL) AZOLILCARBINOLES DERIVATIVES IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF DISORDERS MEDIATED BY AN EXCESS OF SUBSTANCE P.
US6436959B1 (en) * 1998-12-23 2002-08-20 Ortho-Mcneil Pharmaceutical, Inc. 4-[aryl(piperidin-4-yl)]aminobenzamides
US6235900B1 (en) * 1999-02-04 2001-05-22 American Home Products Corporation Tricyclic pyridine N-oxides vasopressin agonists
US6297234B1 (en) * 1999-02-04 2001-10-02 American Home Products Corporation Arylthiophene vasopressin agonists
US6344451B1 (en) * 1999-02-04 2002-02-05 American Home Products Pyrrolobenzodiazepine carboxyamide vasopressin agonists
GB9907571D0 (en) * 1999-04-06 1999-05-26 Zeneca Ltd Compounds
IT1312083B1 (en) * 1999-04-20 2002-04-04 Smithkline Beecham Spa MORPHINOID DERIVATIVES, PROCEDURE FOR THEIR PREPARATION AND THERAPEUTIC USE.
IT1306165B1 (en) * 1999-07-05 2001-05-30 Innova Ltd USE OF INHIBITORS OF THE SUBSTANCE P FOR THE TREATMENT OF DENOCARCINOMAS.
US6384044B1 (en) * 1999-11-29 2002-05-07 Bernard Bihari Method of treating cancer of the prostate
AUPQ514600A0 (en) * 2000-01-18 2000-02-10 James Cook University Brain injury treatment
US6716449B2 (en) * 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
BR0108965A (en) * 2000-03-03 2002-11-26 Ortho Mcneil Pharm Inc Derivatives of 3- (diarylmethylene) -8-azabicyclo [3,2,1] octane
AU4743601A (en) * 2000-03-15 2001-09-24 Wolfgang Sadee Neutral antagonists and use thereof in treating drug abuse
US6525062B2 (en) * 2000-06-09 2003-02-25 The Regents Of The University Of California Method of treating pain using nalbuphine and opioid antagonists
TWI287003B (en) * 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
US6596692B1 (en) * 2000-07-31 2003-07-22 Dabur Research Foundation Substance P analogs for the treatment of cancer
US6569449B1 (en) * 2000-11-13 2003-05-27 University Of Kentucky Research Foundation Transdermal delivery of opioid antagonist prodrugs
EP1342723B1 (en) * 2000-11-22 2008-07-23 Toray Industries, Inc. Indole derivatives and use thereof in medicines
US6437093B1 (en) * 2000-11-28 2002-08-20 Milkhaus Laboratory, Inc. Methods of treatment comprising administration of Substance P
AU2002231206A1 (en) * 2000-12-21 2002-07-01 The Mclean Hospital Corporation Treatment of depression
US6559159B2 (en) * 2001-02-01 2003-05-06 Research Triangle Institute Kappa opioid receptor ligands
US6838580B2 (en) * 2002-01-29 2005-01-04 Teikoku Seiyaku Co., Ltd. Opioid derivative
CA2476218A1 (en) * 2002-02-08 2003-08-14 President And Fellows Of Harvard College Therapeutic compounds
US7594967B2 (en) * 2002-08-30 2009-09-29 Amberwave Systems Corporation Reduction of dislocation pile-up formation during relaxed lattice-mismatched epitaxy
AU2003275433A1 (en) * 2002-10-07 2004-05-04 Synergia Pharma, Inc. Compositions and methods for treating pain
US7820689B2 (en) * 2006-08-10 2010-10-26 Hua-Lin Wu Methods and compositions for preventing or treating cardiovascular disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025157A (en) * 1997-02-18 2000-02-15 Genentech, Inc. Neurturin receptor
US6166008A (en) * 1997-10-27 2000-12-26 Cortex Pharmaceuticals, Inc. Treatment of schizophrenia with ampakines and neuroleptics

Also Published As

Publication number Publication date
EP1809104A2 (en) 2007-07-25
US20060069086A1 (en) 2006-03-30
JP2008514612A (en) 2008-05-08
AU2005286733B2 (en) 2009-11-05
CA2580694A1 (en) 2006-03-30
JP2011137038A (en) 2011-07-14
US20120088756A1 (en) 2012-04-12
CN101065014A (en) 2007-10-31
AU2005286733A1 (en) 2006-03-30
WO2006034343A2 (en) 2006-03-30
EP1809104A4 (en) 2009-04-29
US20100234360A1 (en) 2010-09-16

Similar Documents

Publication Publication Date Title
WO2006034343A3 (en) methods for regulating neurotransmitter systems by inducing counteradaptations
WO2007100775A3 (en) Methods for regulating neurotransmitter systems by inducing counteradaptations
WO2007048087A3 (en) System and method for controlling hypothalamic function via vestibular stimulation
BR0010316A (en) Method and system for obtaining optimized epo dosage regimens for a desired pharmacodynamic / pharmacokinetic response in a patient
EP1582962A3 (en) System and method for protecting media content
WO2003096983A3 (en) Method of treating dyslipidemic disorders
WO2002035832A3 (en) Trick-mode processing for digital video
WO2006029218A3 (en) Apparatus and method for interconnecting a child seat and monitoring system
WO2007070405A3 (en) Remote module incorporation into a container document
WO2005045580A3 (en) System and method for a unified composition engine in a graphics processing system
WO2006118884A3 (en) Drug delivery devices and related components, systems and methods
WO2007024499A3 (en) System and method for administering pluggable user interactive system applications
WO2007108904A3 (en) System and method for editing online documents
WO2004043742A3 (en) Cargo-rataining bar support
WO2007130547A3 (en) Remote module syndication system and method
IL192168A0 (en) System and methods for initiating, maintaining, and delivering personalized information by communication server
WO2006047362A3 (en) Transdermal delivery systems
WO2004047768A3 (en) Buoyant polymer particles delivering therapeutic agents
TW200629154A (en) Attitude insensitive flow device system and method
WO2005088470A3 (en) Systems and methods for identifying complex text in a presentation data stream
WO2006046114A3 (en) Osmotic dosage forms providing ascending drug release, and processes for their preparation
DE602004019197D1 (en) CONTENT DISTRIBUTION SYSTEM WITH INTEGRATED RECORD CONTROL
EP1227618A3 (en) Administration system, apparatus and method and relay server
WO2006053278A3 (en) System and method for securing the intialization of a smartcard controller
WO2007011518A3 (en) Alignment and breaking of mathematical expressions in documents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2580694

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007533610

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1043/KOLNP/2007

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005286733

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2005286733

Country of ref document: AU

Date of ref document: 20050923

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005286733

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005800810

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200580040206.6

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005800810

Country of ref document: EP